Novartis works with 50 molecules in the development of new CART therapies

Source: redaccionmedica.com

The great results obtained with CAR-T therapies in cancer patients in whom chemotherapy has failed have focused the day ‘Towards a greater knowledge of gene therapies. The ABC of CAR-T ‘cellular therapy, a meeting held by Novartis and the Menéndez Pelayo International University (UIMP) at the National School of Health.

Personalized medicine is the key to the treatment and treatment of clinical cases that represent a greater complexity for the National Health System (NHS). In this sense has been pronounced Eva López, medical director of Novartis Oncology, who has explained that: “At present we are working with some 50 molecules in different indications and projects with the aim of stimulating the immune system and targeted treatments to develop therapies CAR-T, which are what ultimately come together in these treatments. ”

“The CAR-T therapies have allowed us to obtain very positive results, it is true that for their development a lot of time is required and they are a challenge, but thanks to the effort we have already obtained two indications, one pediatric and the other in adults”, has assured Lopez.

In addition, López wanted to emphasize that: “Novartis leads clinical oncological research in Spain, especially in the early stages”. Finally, the medical director of Novartis Oncology has affirmed that the CAR-T studies and therapies have the objective of “rescuing all those people who until now have not been able to be rescued”.

Success of CAR-T
Susana Rives, a doctor from the Pediatric Hematology and Oncology Service of the Sant Joan de Déu Hospital, explained that: “Thanks to the CAR-T therapy, we were able to save a 7-year-old patient who presented a particularly serious condition in 2016. The child had rejected a second bone marrow transplant and relapsed in his acute lymphoblastic leukemia.As we decided to try the CAR-T treatment and since the spring of 2016 the patient has been able to return to normal, now goes to school without any problem ”

Finally, Joaquín Martínez, doctor of the Hematology and Hemotherapy Service of Hospital 12 de Octubre, wanted to emphasize that CAR-T therapies are complex treatments, which can not be accessed by all patients, but represent “hope for those to those who in many cases could only be offered palliative care “.

In Distefar we echo this news, which aims to increase awareness of CART therapies

Epigraph	Basic information Data Protection
Responsable	DISTEFAR DEL SUR, S.L.
Purpose	Process your inquiry / request Detailed information on Data Protection
Legitimation	Consent Detailed information on Data Protection
Recipients	It is not expected to carry out data communications to third parties, except legal obligation Transfers of data to third countries outside the European Union will not be carried out Detailed information on Data Protection
Rights	You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection
Additional Information	You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

CENTRAL

MADRID DELEGATION

Links of interest

Novartis works with 50 molecules in the development of new CART therapies

Related entries

Regional health officials and Farmaindustria meet to analyse new pharmaceutical regulations, the proper use of medicines and advances in digital health

Spain has more than 1,050 clinical trials for rare diseases underway and nine out of ten are promoted by the pharmaceutical industry.

Distefar has been present at the European Clinical Trial Supply and Temperature controlled logistics in Biopharmaceuticals 2025, on 25th and 26th of February.